ClinicalTrials.gg
RecruitingNCT07944378LOHKALTUpdated Nov 18, 2026

A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia

A Phase 4 interventional study of Lokelma in Hyperkalemia, sponsored by AstraZeneca. Recruiting at 4 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by AstraZeneca · Phase 4, Interventional, and Other

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 39 studies in Hyperkalemia by AstraZeneca — 2 open to participants now, 3 under way, 1 of them phase 3. Hyperkalemia · AstraZeneca.

Planned enrollment
17th of 25
120 · median 150
Started
2026
with 1 other
Phase 4
5 of 39
1 open now
Registered
39th of 39
by date

Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 17th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 4, and was the 39th registered.

Hyperkalemia

133 studies on the registry are indexed under Hyperkalemia; 25 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

2 of the 39 studies in Hyperkalemia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 15 Hyperkalemia studies recruiting now, 10 (67%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Hyperkalemia by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase IV, multicentre, open-label, non-comparative study evaluating Lokelma (sodium zirconium cyclosilicate, SZC) in approximately 100 Indian adults with mild to moderate hyperkalaemia.

Read the detailed description

The primary objective is to assess safety through treatment-emergent adverse events, serious adverse events and discontinuations due to adverse events. Secondary objectives are to assess effectiveness of Lokelma through serum potassium reduction, achievement and maintenance of normokalaemia, while an exploratory objective focuses on continuation or initiation of RAAS inhibitor therapy. Each participant is followed for approximately 3.5 months, including treatment and a safety follow-up seven days after the final dose.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Participant must be ≥ 18 years of age, at the time of signing the .

      • Participants with mild to moderate hyperkalaemia- the potassium values between 5.1 to 6.4 mmol/L inclusive, at screening (Day 0)
      • Ability to have repeated blood draws or effective venous catheterisation.
      • use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. i) FOCBP must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening. The female participants should be on stable on their chosen method of birth control for minimum of one month before entering the study and willing to remain on the birth control until 7 days after the last dose. ii) Female participants who are surgically sterile or those who are (if they have been amenorrhoeic for 12 months prior to the planned date of screening without an alternative medical cause) are not considered to be of .
      • Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • As judged by the investigator, any evidence of oedema which in the investigator's opinion makes it undesirable for the participant to participate in the study.

    • Patients undergoing haemodialysis or a prospective candidate for haemodialysis.
    • Pseudo hyperkalaemia signs and symptoms, such as excessive fist clenching haemolysed blood specimen, severe leucocytosis or thrombocytosis.
    • Participants with a of \< 12 months.
    • Participants who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the participants' tasks associated with the protocol.
    • Women who are pregnant, lactating, or planning to become pregnant.
    • Participants with diabetic ketoacidosis.
    • Presence of any condition which, in the opinion of the investigator, places the participant at undue risk.
    • Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
    • Participants with cardiac arrhythmias requiring immediate treatment.
    • Participants with history of associated with other medications that required discontinuation of that medication.
    • Participants with congenital long QT syndrome.
    • Participants treated with lactulose, rifaximin or other non-absorbed antibiotics for hyperammonaemia within the last 7 days.
    • Participants treated with resins (such as sevelamer acetate), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.
    • Participants treated with SPS or SZC (microporous, fractionated, protonated zirconium silicate), CPS or patiromer within the last 7 days.
    • Known or previous anaphylaxis to SZC or to components or any of the of the product.
    • Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
    • Prior (within last 1 month) and ongoing participation in another clinical trial, observational study, and real-world evidence study.
    • Positive antibody, virus surface antigen, or hepatitis B virus core antibody, at screening.
    • Known to have tested positive for .
    • Documented \< 15 mL/min/1.73 m2 within 90 days before study entry.
    • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
    • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention

    Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g

    Drug: Lokelma

Interventions

  • DrugLokelma

    Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g

06

What researchers measure

Primary outcomes

  1. Incidence of TEAEs, SAEs, and DAEs.

    Number and proportion of participants with TEAEs SAEs, and DAEs. Incidence rates summarised by patients with events per 100 patient-years.

    Time frame: Day 86

  2. Causal relationship of TEAEs, SAEs, and DAEs

    Nature, intensity and causal relationship of TEAEs, SAEs, and DAEs

    Time frame: Day 86

Secondary outcomes

  1. Exponential rate of change in S-K values

    Rate of Change in S-K values

    Time frame: Day 4

  2. Proportion of participants who achieve normokalaemia

    Number of study subjects achieving normal potassium levels

    Time frame: Day 4

  3. Mean change and mean percent change from baseline in S-K values

    Mean change and mean percent change from baseline in S-K values over time until EOT

    Time frame: Day 86

  4. Proportions of participants maintaining normokalaemia

    Number participants maintaining normal potassium levels at EOT

    Time frame: Day 86

07

Study locations

4 of 4 sites recruiting
  • Research Site
    Ahmedabad, 380013, India
    Recruiting
  • Research Site
    Ahmedabad, 380052, India
    Recruiting
  • Research Site
    Kolkata, 700020, India
    Recruiting
  • Research Site
    Secunderabad, 500003, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 16 phase 4 interventional studies under Hyperkalemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartActual
Aug 8, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944378
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Aug 8, 2026
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion